2022
Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2018
Training social workers to enhance patient-centered care for drug-resistant TB-HIV in South Africa
Zelnick J, Seepamore B, Daftary A, Amico K, Bhengu X, Friedland G, Padayatchi N, Naidoo K, O'Donnell M. Training social workers to enhance patient-centered care for drug-resistant TB-HIV in South Africa. Public Health Action 2018, 8: 25-27. PMID: 29581940, PMCID: PMC5858062, DOI: 10.5588/pha.17.0114.Peer-Reviewed Original ResearchDrug-resistant tuberculosisHuman immunodeficiency virusPatient-centered careHIV coinfectionSupport group facilitationTB-HIVHIV outcomesMedication adherenceImmunodeficiency virusTreatment literacyQuestionnaire scoresCareSocial workersTraining interventionBrief training interventionCoinfectionLower ratesTraining coursesPilot training courseKwaZulu-NatalUnique roleTuberculosisWorkersCourse
2017
Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts
Shenoi SV, Moll AP, Brooks RP, Kyriakides T, Andrews L, Kompala T, Upadhya D, Altice FL, Eksteen FJ, Friedland G. Integrated Tuberculosis/Human Immunodeficiency Virus Community-Based Case Finding in Rural South Africa: Implications for Tuberculosis Control Efforts. Open Forum Infectious Diseases 2017, 4: ofx092. PMID: 28695145, PMCID: PMC5499582, DOI: 10.1093/ofid/ofx092.Peer-Reviewed Original ResearchHuman immunodeficiency virusIntensive case findingCase findingResistant TBTB casesHIV testingRural South AfricaOverall case notification rateConcurrent HIV testingHIV coinfection rateHIV-negative tuberculosisMedian CD4 countCD4 cell countHIV/TBDrug-resistant TBCase notification ratesCase-finding strategyHIV-positive individualsHigh-risk populationTB symptom screeningPopulation-level ratesCD4 countTuberculosis symptomsSymptom screeningTB elimination
2016
Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV
O'Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, Wolf A, Metcalfe JZ, Isaakidis P, Davis JL, Zelnick JR, Brust JC, Naidu N, Garretson M, Bangsberg DR, Padayatchi N, Friedland G. Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. The International Journal Of Tuberculosis And Lung Disease 2016, 20: 430-434. PMID: 26970149, PMCID: PMC4863995, DOI: 10.5588/ijtld.15.0360.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug-resistant TBMedication adherenceNational TB Control ProgrammeDrug-resistant tuberculosisTB control programsPatient-centered modelPatient-centered careNew antimycobacterial agentsUnderstanding of adherenceHealth care systemAdherence supportTB-HIVObserved therapyImmunodeficiency virusComprehensive careTreatment outcomesTreatment supportTuberculosis diagnosticsPatientsCare systemCareAntimycobacterial agentsTreatment deliveryAdherence
2015
Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011
Cowell A, Shenoi SV, Kyriakides TC, Friedland G, Barakat LA. Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011. Journal Of Hospital Medicine 2015, 10: 608-614. PMID: 26130520, PMCID: PMC4560992, DOI: 10.1002/jhm.2409.Peer-Reviewed Original ResearchConceptsHospital deathAIDS deathsHuman immunodeficiency virus-infected patientsHigher CD4 cell countsAIDS infectionAntiretroviral therapy eraNon-AIDS deathsNon-AIDS malignanciesCD4 cell countHIV viral loadVirus-infected patientsHuman immunodeficiency virusUrban teaching hospitalTimes greater likelihoodCardiovascular comorbiditiesTherapy eraCD4 countInpatient mortalityImmunodeficiency syndromeLiver diseaseUnderlying liverViral loadImmunodeficiency virusMedical recordsAntiretroviral era
2012
Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa
Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, Mathema B, Shashkina E, Rothenberg R, Moll AP, Friedland G, Sturm AW, Shah NS. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. The Journal Of Infectious Diseases 2012, 207: 9-17. PMID: 23166374, PMCID: PMC3523793, DOI: 10.1093/infdis/jis631.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsCluster AnalysisCross InfectionDrug Therapy, CombinationEthambutolExtensively Drug-Resistant TuberculosisFemaleGenotypeHIV InfectionsHospitals, RuralHumansIsoniazidMaleMutationMycobacterium tuberculosisPolymorphism, Restriction Fragment LengthPrevalencePyrazinamideRetrospective StudiesRifampinSequence Analysis, DNASouth AfricaConceptsDrug-resistant tuberculosisHuman immunodeficiency virusNosocomial transmissionEpidemiologic linkExtensively Drug-Resistant TuberculosisPoor infection controlSmear-positive tuberculosisMultidrug-resistant tuberculosisHigh HIV prevalencePoint-source outbreakGlobal public health threatPublic health threatResistance-determining regionXDR tuberculosisImmunodeficiency virusHIV prevalenceObservational studyInfection controlRural hospitalsPatientsTuberculosisTugela FerryFragment length polymorphism analysisHealth threatRestriction fragment length polymorphism analysisRisk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2010
Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa.
Thomas TA, Shenoi SV, Heysell SK, Eksteen FJ, Sunkari VB, Gandhi NR, Friedland G, Shah NS. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. The International Journal Of Tuberculosis And Lung Disease 2010, 14: 1244-51. PMID: 20843414, PMCID: PMC3030274.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusXDR-TB diagnosisXDR-TBDrug-resistant tuberculosisPediatric wardImmunodeficiency virusRural South AfricaXDR-TB patientsXDR-TB treatmentActive antiretroviral therapySputum culture conversionNeuropsychiatric side effectsHospital pediatric wardInfection control policiesCulture conversionAntiretroviral therapyRadiographic improvementNosocomial transmissionOverlapping toxicitiesMicrobiologic dataHIV treatmentMedical recordsMicrobiologic diagnosisHIV therapyPrevious historyTiming of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2008
Mild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen Quality of Life in HIV-Infected Individuals
Mannheimer SB, Wold N, Gardner EM, Telzak EE, Hullsiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G, AIDS T. Mild-to-Moderate Symptoms during the First Year of Antiretroviral Therapy Worsen Quality of Life in HIV-Infected Individuals. Clinical Infectious Diseases 2008, 46: 941-945. PMID: 18279044, DOI: 10.1086/528859.Peer-Reviewed Original Research
2007
Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean change
2006
Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increaseInteractions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphine
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical services
2003
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal Of Urban Health 2003, 80: 416-427. PMID: 12930880, PMCID: PMC3455979, DOI: 10.1093/jurban/jtg053.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusNondetectable viral loadCD4 lymphocyte countDrug treatmentDrug usersLymphocyte countViral loadHIV therapyBaseline HIV-1 RNA levelsNeedle exchangeHealth servicesHIV-1 RNA levelsPilot studyPotent antiretroviral combinationUtilization of HAARTActive antiretroviral therapyAntiretroviral therapy regimensHIV-1 RNACommunity-based health interventionsAdverse side effectsActive drug usersFormal drug treatmentImmunodeficiency syndrome (AIDS) incidenceSmall pilot studyActive heroin injectors
2002
The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials
Mannheimer S, Friedland G, Matts J, Child C, Chesney M, AIDS T. The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus—Infected Persons in Clinical Trials. Clinical Infectious Diseases 2002, 34: 1115-1121. PMID: 11915001, DOI: 10.1086/339074.Peer-Reviewed Original ResearchConceptsHIV RNA levelsHuman immunodeficiency virusImmunodeficiency virusClinical trialsRNA levelsPlasma HIV RNA levelsBiologic outcomesConsistency of adherenceCopies/mLMulticenter clinical trialAntiretroviral therapyCD4 countMonth 12Nonwhite racePoor adherenceAdherence levelsAdherence patternsOlder ageGood adherenceAdherenceCells/TrialsVisitsOutcomesParticipants
2001
Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition
McCance‐Katz E, Rainey P, Friedland G, Kosten T, Jatlow P. Effect of Opioid Dependence Pharmacotherapies on Zidovudine Disposition. American Journal On Addictions 2001, 10: 296-307. PMID: 11783744, DOI: 10.1111/j.1521-0391.2001.tb00519.x.Peer-Reviewed Original ResearchConceptsOpioid-dependence pharmacotherapyHuman immunodeficiency virusZDV toxicityActive antiretroviral therapyInjection drug usersTime-concentration curveZDV pharmacokineticsZidovudine dispositionAntiretroviral therapyOpioid pharmacotherapyDose adjustmentOpioid dependenceImmunodeficiency virusZDV concentrationsControl subjectsMethadone maintenanceDrug usersPharmacotherapyZidovudineBuprenorphineNaltrexoneSignificant differencesLAAMToxicitySubjects
2000
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy
Havlir D, Tierney C, Friedland G, Pollard R, Smeaton L, Sommadossi J, Fox L, Kessler H, Fife K, Richman D. In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy. The Journal Of Infectious Diseases 2000, 182: 321-325. PMID: 10882616, DOI: 10.1086/315683.Peer-Reviewed Original ResearchConceptsCD4 cell countD4TCell countD4T armD4T monotherapyWeeks of therapyHuman immunodeficiency virusCopies/mLGreater antiviral activityT monotherapyHIV RNACurrent regimenImmunodeficiency virusPharmacologic antagonismCombination therapyMean reductionZidovudineAntiviral activityVivo antagonismProgressive declinePatientsCells/DdIIntracellular levelsTherapy
1998
Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance
Wainberg M, Friedland G. Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance. JAMA 1998, 279: 1977-1983. PMID: 9643862, DOI: 10.1001/jama.279.24.1977.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug-resistant variantsDrug-resistant virusesHIV drug resistanceAntiviral therapyPublic health implicationsDrug resistanceGenital secretionsHealth implicationsPublic health importanceAntiretroviral therapyViral burdenAntiretroviral agentsPatient adherenceTreatment failureViral loadImmunodeficiency virusResistant virusesSustained reductionHealth importanceTherapyVirusChild routeBloodSecretion
1990
Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus.
Feingold AR, Vermund SH, Burk RD, Kelley KF, Schrager LK, Schreiber K, Munk G, Friedland GH, Klein RS. Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 896-903. PMID: 2166784.Peer-Reviewed Original ResearchConceptsSquamous intraepithelial lesionsHIV-positive womenCervical cytologic abnormalitiesCytologic abnormalitiesCervical cytologyAsymptomatic HIV-positive womenHuman immunodeficiency virus (HIV) infectionHIV-negative womenHuman papillomavirus infectionImmunodeficiency virus infectionSymptomatic HIV infectionIntravenous drug useHuman immunodeficiency virusIntravenous drug usersFemale genital tractWestern blot confirmationCervicovaginal lavageHPV determinationSeronegative womenHPV infectionPapillomavirus infectionCytological lesionsHIV infectionIntraepithelial lesionsImmunodeficiency virus